DE602006020057D1 - A1-adenosinrezeptoragonisten - Google Patents

A1-adenosinrezeptoragonisten

Info

Publication number
DE602006020057D1
DE602006020057D1 DE602006020057T DE602006020057T DE602006020057D1 DE 602006020057 D1 DE602006020057 D1 DE 602006020057D1 DE 602006020057 T DE602006020057 T DE 602006020057T DE 602006020057 T DE602006020057 T DE 602006020057T DE 602006020057 D1 DE602006020057 D1 DE 602006020057D1
Authority
DE
Germany
Prior art keywords
adenosine receptor
receptor agonist
angina
release
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006020057T
Other languages
German (de)
English (en)
Inventor
Elfatih Elzein
Xiaofen Li
Jeff Zablocki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of DE602006020057D1 publication Critical patent/DE602006020057D1/de
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE602006020057T 2005-10-13 2006-10-11 A1-adenosinrezeptoragonisten Active DE602006020057D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72661605P 2005-10-13 2005-10-13
PCT/US2006/039975 WO2007047401A2 (en) 2005-10-13 2006-10-11 A1 adenosine receptor agonists

Publications (1)

Publication Number Publication Date
DE602006020057D1 true DE602006020057D1 (de) 2011-03-24

Family

ID=37865975

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006020057T Active DE602006020057D1 (de) 2005-10-13 2006-10-11 A1-adenosinrezeptoragonisten

Country Status (8)

Country Link
US (2) US7488720B2 (cg-RX-API-DMAC7.html)
EP (1) EP1943251B8 (cg-RX-API-DMAC7.html)
JP (1) JP2009511593A (cg-RX-API-DMAC7.html)
AT (1) ATE497960T1 (cg-RX-API-DMAC7.html)
CA (1) CA2625783A1 (cg-RX-API-DMAC7.html)
DE (1) DE602006020057D1 (cg-RX-API-DMAC7.html)
ES (1) ES2358351T3 (cg-RX-API-DMAC7.html)
WO (1) WO2007047401A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488720B2 (en) * 2005-10-13 2009-02-10 Cv Therapeutics, Inc. A1 adenosine receptor agonists
CN101712709A (zh) * 2008-10-06 2010-05-26 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷及其调血脂的用途
CN120647702A (zh) 2017-05-19 2025-09-16 全技术公司 药剂、组合物及其相关方法
EP4541803A4 (en) * 2022-06-17 2025-10-01 Shanghai Senhui Medicine Co Ltd CYCLOPENTYLADENOSINE DERIVATIVE AND ITS PHARMACEUTICAL USE

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
ES2264826T3 (es) * 1998-10-16 2007-01-16 Pfizer Inc. Derivados de adenina.
US20030013675A1 (en) * 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
US20030078232A1 (en) 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
WO2004069185A2 (en) * 2003-02-03 2004-08-19 Cv Therapeutics Inc. Partial and full agonists of a1 adenosine receptors
US7488720B2 (en) * 2005-10-13 2009-02-10 Cv Therapeutics, Inc. A1 adenosine receptor agonists

Also Published As

Publication number Publication date
EP1943251A2 (en) 2008-07-16
WO2007047401A3 (en) 2007-06-14
ATE497960T1 (de) 2011-02-15
ES2358351T8 (es) 2011-06-15
JP2009511593A (ja) 2009-03-19
WO2007047401A2 (en) 2007-04-26
CA2625783A1 (en) 2007-04-26
US20090137520A1 (en) 2009-05-28
US20070087994A1 (en) 2007-04-19
US7488720B2 (en) 2009-02-10
EP1943251B8 (en) 2011-03-23
ES2358351T3 (es) 2011-05-09
EP1943251B1 (en) 2011-02-09

Similar Documents

Publication Publication Date Title
CL2011000978A1 (es) Compuestos derivados de fenil-amida o piridil-amida, agonistas de gpbar1; proceso de preparacion; composicion farmaceutica; y su uso en diabetes, isquemia, obesidad, dislipidemia, entre otras.
MY180473A (en) Imaging and evaluating embryos, oocytes, and stem cells
CL2009001476A1 (es) Compuestos derivados de 2,4-diamin-n2-fenil pirimidina sustituidos, mediadores de la inhibicion de igf-1r; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades autoinmune, por trasplante, infecciosas o un trastorno proliferativo celular.
Ligasová et al. A fatal combination: a thymidylate synthase inhibitor with DNA damaging activity
EA200800100A1 (ru) Соединения азаиндазола и способы применения
EA200800727A1 (ru) Введение ингибиторов дипептидилпептидазы
ECSP11010798A (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
EA200800726A1 (ru) Введение ингибиторов дипептидилпептидазы
BRPI0911273A2 (pt) inibidor de dpp-iv combinado com outro agente antidiabético, comprimidos que compreendem tais formulações, seu uso e processo para sua preparação
ES2337973B8 (es) Adenovirus auxiliares auto-inactivantes para la produccion de adenovirus recombinantes de alta capacidad.
Fu et al. Direct repair of 3, N4-ethenocytosine by the human ALKBH2 dioxygenase is blocked by the AAG/MPG glycosylase
EA201071221A1 (ru) Гетероциклические соединения
ATE497960T1 (de) A1-adenosinrezeptoragonisten
EA200701600A1 (ru) Способ получения лёгкодоступного клеточного материала из периферической крови и композиция на его основе
PE20060558A1 (es) Conjugados para el diagnostico de enfermedades asociadas con angiogenesis que comprenden un ligante especifico para angiogenesis y una tintura de cianina
TW200616649A (en) Partial and full agonists of A1 adenosine receptors
EA200701592A1 (ru) Композиты и способы их получения и использования
ECSP077845A (es) Composiciones y sales dermatológicas para el tratamiento de enfermedades dermatológicas
Lan et al. Rho-kinase mediated cytoskeletal stiffness in skinned smooth muscle
WO2008058238A3 (en) Adenosine a1 and a3 receptor gene sequence variations for predicting disease outcome and treatment outcome
ATE474834T1 (de) Als agonisten des gpr38-rezeptors geeignete biarylverbindungen
BRPI0717448A2 (pt) Composição detergente sólida para lavagem de roupas altamente solúvel em água, de baixa densidade e baixo builder
TW200621793A (en) Partial and full agonists of a1 adenosine receptors
CL2013001601A1 (es) Proceso para licuar una o mas proteinas de cereal, que comprende las etapas de : a) suministrar una composicion que comprende una o mas de proteinas de cereal de un 5-40% en peso de materia seca; b) añadir una o mas enzimas hidroliticas y/o auxiliares de procesamiento; c) opcionalmente, preacondicionar; d) homogeneizar; ademas opcionalmente pretratar la composicion obtenida, e incubar la composicion a una temperatura de 50-85 grados celsius durante al menos 5 minutos.
WO2006116197A3 (en) Methods of identifying individuals at risk of perioperative myocardial injury, major adverse cardiac events, cognitive decline, arrhythmias, depression or bleeding

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: GILEAD PALO ALTO, INC., FOSTER CITY, CALIF., US